Overview
Currently there is little standardization between rTMS treatment programs as to what is the best way to localize the left dorsolateral prefrontal cortex, which is the FDA-approved treatment location for clinical rTMS for major depressive disorder (MDD). Different targeting methods yield locations that can vary by up to a few centimeters. By comparing different treatment locations and obtaining neurobehavioral, neuroimaging, cognitive, and neuropsychological measures, this study would provide the opportunity to identify the optimal treatment targeting method when using rTMS for major depressive disorder in a clinical setting. This study will specifically be focusing on comparing the two most common targeting methods: a target 5.5cm anterior to the motor strip on the left prefrontal scalp and the F3 target location on the left prefrontal scalp as identified using the 10-20 EEG system nomenclature.
Principal investigator
Eligibility criteria
* Diagnosis of major depressive disorder
* Age between 18 and 90 years
* rTMS is clinically indicated as determined by clinical rTMS physician team at University of Iowa
Exclusion Criteria:
* rTMS contraindication such as implanted ferromagnetic material in the head or history of epilepsy with poorly controlled seizures
* MRI exclusion criteria (if participating in MRI portion of study) including implanted device such as:
* Pacemaker
* Coronary Stent
* Defibrillator
* Neurostimulation
* Or any of the following conditions:
* Claustrophobia
* Uncontrolled high blood pressure
* Poorly controlled atrial fibrillation
* Significant heart disease
* Hemodynamic instability
* Severe kidney disease
* Pregnant, trying to become pregnant, or breast feeding
For Referring Providers
Do you have a patient you think would be a good candidate for this trial? Learn more about enrolling your patient.